{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:35:24Z","timestamp":1761964524560},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2013,10,25]],"date-time":"2013-10-25T00:00:00Z","timestamp":1382659200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0076713","type":"journal-article","created":{"date-parts":[[2013,10,25]],"date-time":"2013-10-25T21:22:41Z","timestamp":1382736161000},"page":"e76713","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["Impact of Three Oral Antidiabetic Drugs on Markers of \u03b2-Cell Function in Patients with Type 2 Diabetes: A Meta-Analysis"],"prefix":"10.1371","volume":"8","author":[{"given":"Jin","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajie","family":"Zang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huihua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,10,25]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","article-title":"Use and abuse of HOMA modeling","volume":"27","author":"TM Wallace","year":"2004","journal-title":"Diabetes Care"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"E155","DOI":"10.1152\/ajpendo.00104.2002","article-title":"Basal and dynamic proinsulin-insulin relationship to assess beta-cell function during OGTT in metabolic disorders","volume":"285","author":"A Tura","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1742-1241.2007.01360.x","article-title":"The importance of beta-cell management in type 2 diabetes","volume":"Suppl 153","author":"E Standl","year":"2007","journal-title":"Int J Clin Pract"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1007\/s00125-007-0806-x","article-title":"Relationship between Insulin Sensitivity and Cardiovascular Disease Risk (RISC) Project Investigators (2007) Association of fasting glucagon and proinsulin concentrations with insulin resistance","volume":"50","author":"E Ferrannini","year":"2007","journal-title":"Diabetologia"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1210\/10.1210\/er.2006-0038","article-title":"\u03b2-Cell failure in diabetes and preservation by clinical treatment","volume":"28","author":"BL Wajchenberg","year":"2007","journal-title":"Endocr Rev"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.diabres.2007.03.014","article-title":"Relationship between proinsulin-to-insulin ratio and advanced glycation end products in Japanese type 2 diabetic subjects","volume":"78","author":"Y Saisho","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.2337\/dc11-2170","article-title":"\u03b2-cell function preservation after 3.5 years of intensive diabetes therapy","volume":"35","author":"LB Harrison","year":"2012","journal-title":"Diabetes Care"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy","volume":"355","author":"SE Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/MAJ.0b013e31818eb721","article-title":"Impact of sitagliptin on markers of \u03b2-cell function: a meta-analysis","volume":"337","author":"DM Riche","year":"2009","journal-title":"Am J Med Sci"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"AR Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"JP Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates","volume":"326","author":"DG Altman","year":"2003","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1185\/03007990802705679","article-title":"Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study","volume":"25","author":"D Williams-Herman","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.2337\/dc07-0627","article-title":"Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes","volume":"30","author":"BJ Goldstein","year":"2007","journal-title":"Diabetes Care"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1463-1326.2009.01187.x","article-title":"Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes","volume":"12","author":"P Aschner","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1463-1326.2011.01390.x","article-title":"The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus","volume":"13","author":"C Reasner","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1742-1241.2006.01246.x","article-title":"Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes","volume":"61","author":"R Scott","year":"2007","journal-title":"Int J Clin Pract"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.2337\/dc06-0703","article-title":"Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes","volume":"29","author":"P Aschner","year":"2006","journal-title":"Diabetes Care"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1007\/s00125-006-0416-z","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus","volume":"49","author":"I Raz","year":"2006","journal-title":"Diabetologia"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1185\/030079907X188152","article-title":"Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes","volume":"23","author":"M Hanefeld","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.diabres.2007.08.021","article-title":"Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes","volume":"79","author":"K Nonaka","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1463-1326.2011.01530.x","article-title":"Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes","volume":"14","author":"J Wainstein","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1464-5491.2004.01218.x","article-title":"An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study","volume":"21","author":"TM Wallace","year":"2004","journal-title":"Diabet Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2796.2006.01665.x","article-title":"Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes","volume":"260","author":"M Dorkhan","year":"2006","journal-title":"J Intern Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12020-009-9174-2","article-title":"Insulin-dependent actions of pioglitazone in newly diagnosed, drug na\u00efve patients with type 2 diabetes","volume":"35","author":"E Kutoh","year":"2009","journal-title":"Endocrine"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2265.2011.04240.x","article-title":"Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study","volume":"77","author":"S Lim","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.metabol.2009.10.007","article-title":"Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients","volume":"59","author":"G Derosa","year":"2010","journal-title":"Metabolism"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/j.1463-1326.2007.00839.x","article-title":"Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes","volume":"10","author":"R Scott","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/j.1463-1326.2009.01055.x","article-title":"Earlier triple therapy with pioglitazone in patients with type 2 diabetes","volume":"11","author":"G Charpentier","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.clinthera.2006.10.007","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"28","author":"J Rosenstock","year":"2006","journal-title":"Clin Ther"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2337\/diabetes.52.1.102","article-title":"\u03b2-Cell deficit and increased \u03b2-cell apoptosis in humans with type 2 diabetes","volume":"52","author":"AE Butler","year":"2003","journal-title":"Diabetes"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.2337\/db05-1602","article-title":"Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic b-cell massand function in a rodent model of type 2 diabetes","volume":"55","author":"J Mu","year":"2006","journal-title":"Diabetes"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1146\/annurev.med.57.110104.115624","article-title":"Therapeutic approaches to preserve islet mass in type 2 diabetes","volume":"57","author":"LL Baggio","year":"2006","journal-title":"Annu Rev Med"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.2337\/diabetes.51.2007.S134","article-title":"Lipotoxicity in human pancreatic islets and the protective effect of metformin","volume":"51","author":"R Lupi","year":"2002","journal-title":"Diabetes"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2337\/diabetes.55.02.06.db05-1066","article-title":"Effect of pioglitazone on pancreatic \u03b2-cell function and diabetes risk in Hispanic women with prior gestational diabetes","volume":"55","author":"AH Xiang","year":"2006","journal-title":"Diabetes"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1055\/s-2004-826163","article-title":"Beta- and alpha-cell dysfunction in type 2diabetes","volume":"36","author":"S Del Prato","year":"2004","journal-title":"Horm Metab Res"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1089\/152091504774198124","article-title":"Role of intact proinsulin in diagnosis and treatment of type 2 diabetes mellitus","volume":"6","author":"A Pf\u00fctzner","year":"2004","journal-title":"Diabetes Technol Ther"},{"key":"ref38","first-page":"13","article-title":"Insulinotropic action of AICA riboside. Insulin release by isolated islets and the perfused pancreas","volume":"25","author":"AG Akkan","year":"1994","journal-title":"Diabetes Res"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"10341","DOI":"10.1074\/jbc.M610631200","article-title":"The role of AMPK and mTOR in nutrient sensing in pancreatic beta-cells","volume":"282","author":"CE Gleason","year":"2007","journal-title":"J Biol Chem"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2337\/diabetes.52.3.741","article-title":"Dipeptidyl peptidase IV inhibitor treatment stimulates \u03b2-cell survival and islet neogenesis in streptozotocin-induced diabetic rats","volume":"52","author":"JA Pospisilik","year":"2003","journal-title":"Diabetes"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"6825","DOI":"10.1073\/pnas.0631828100","article-title":"Mice lacking dipeptidylpeptidase IV are protected against obesity and insulin resistance","volume":"100","author":"SL Conarello","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/clpt.2010.184","article-title":"Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1","volume":"88","author":"EM Migoya","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1210\/en.2002-0068","article-title":"Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase","volume":"144","author":"JA Ehses","year":"2003","journal-title":"Endocrinology"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0076713","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T03:47:40Z","timestamp":1540266460000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0076713"}},"subtitle":[],"editor":[{"given":"Bridget","family":"Wagner","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,10,25]]},"references-count":43,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2013,10,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0076713","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,25]]}}}